178 related articles for article (PubMed ID: 27779248)
1. Association of CTH variant with sinusoidal obstruction syndrome in children receiving intravenous busulfan and cyclophosphamide before hematopoietic stem cell transplantation.
Huezo-Diaz Curtis P; Uppugunduri CRS; Muthukumaran J; Rezgui MA; Peters C; Bader P; Duval M; Bittencourt H; Krajinovic M; Ansari M
Pharmacogenomics J; 2018 Jan; 18(1):64-69. PubMed ID: 27779248
[TBL] [Abstract][Full Text] [Related]
2. Analysis of glutathione S-transferase and cytochrome P450 gene polymorphism in recipients of dose-adjusted busulfan-cyclophosphamide conditioning.
Terakura S; Onizuka M; Fukumoto M; Kuwatsuka Y; Kohno A; Ozawa Y; Miyamura K; Inagaki Y; Sawa M; Atsuta Y; Suzuki R; Naoe T; Morishita Y; Murata M;
Int J Hematol; 2020 Jan; 111(1):84-92. PubMed ID: 31555969
[TBL] [Abstract][Full Text] [Related]
3. Reduced Risk of Sinusoidal Obstruction Syndrome of the Liver after Busulfan-Cyclophosphamide Conditioning Prior to Allogeneic Hematopoietic Stem Cell Transplantation.
El-Serafi I; Remberger M; Ringdèn O; Törlén J; Sundin M; Björklund A; Winiarski J; Mattsson J
Clin Transl Sci; 2020 Mar; 13(2):293-300. PubMed ID: 31675173
[TBL] [Abstract][Full Text] [Related]
4. Association Between the Magnitude of Intravenous Busulfan Exposure and Development of Hepatic Veno-Occlusive Disease in Children and Young Adults Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation.
Bognàr T; Bartelink IH; Egberts TCG; Rademaker CMA; Versluys AB; Slatter MA; Kletzel M; Nath CE; Cuvelier GDE; Savic RM; Dvorak C; Long-Boyle JR; Cowan MJ; Bittencourt H; Bredius RGM; Güngör T; Shaw PJ; Ansari M; Hassan M; Krajinovic M; Hempel G; Marktel S; Chiesa R; Théoret Y; Lund T; Orchard PJ; Wynn RF; Boelens JJ; Lalmohamed A
Transplant Cell Ther; 2022 Apr; 28(4):196-202. PubMed ID: 35065280
[TBL] [Abstract][Full Text] [Related]
5. Heparanase polymorphisms: influence on incidence of hepatic sinusoidal obstruction syndrome in children undergoing allogeneic hematopoietic stem cell transplantation.
Seifert C; Wittig S; Arndt C; Gruhn B
J Cancer Res Clin Oncol; 2015 May; 141(5):877-85. PubMed ID: 25335953
[TBL] [Abstract][Full Text] [Related]
6. Targeted-dose of busulfan: Higher risk of sinusoidal obstructive syndrome observed with systemic exposure dose above 5000 µMol⸱min. A historically controlled clinical trial.
Esteves I; Santos FPS; Ribeiro AAF; Seber A; Sugawara EK; Sobrinho JJDN; Barros JC; Oliveira JSR; Fernandes JF; Hamerschlak N; Andersson BS; de Lima M; Kerbauy FR
Hematol Oncol; 2020 Dec; 38(5):773-781. PubMed ID: 32779746
[TBL] [Abstract][Full Text] [Related]
7. Economic and clinical aspects of intravenous versus oral busulfan in adult patients for conditioning prior to HSCT.
Berger K; Schopohl D; Rieger C; Ostermann H
Support Care Cancer; 2015 Dec; 23(12):3447-54. PubMed ID: 25773673
[TBL] [Abstract][Full Text] [Related]
8. Influence of glutathione S-transferase A1, P1, M1, T1 polymorphisms on oral busulfan pharmacokinetics in children with congenital hemoglobinopathies undergoing hematopoietic stem cell transplantation.
Elhasid R; Krivoy N; Rowe JM; Sprecher E; Adler L; Elkin H; Efrati E
Pediatr Blood Cancer; 2010 Dec; 55(6):1172-9. PubMed ID: 20672371
[TBL] [Abstract][Full Text] [Related]
9. Precision dosing of intravenous busulfan in pediatric hematopoietic stem cell transplantation: Results from a multicenter population pharmacokinetic study.
Ben Hassine K; Nava T; Théoret Y; Nath CE; Daali Y; Kassir N; Lewis V; Bredius RGM; Shaw PJ; Bittencourt H; Krajinovic M; Uppugunduri CRS; Ansari M
CPT Pharmacometrics Syst Pharmacol; 2021 Sep; 10(9):1043-1056. PubMed ID: 34453497
[TBL] [Abstract][Full Text] [Related]
10. Genetic Susceptibility to Hepatic Sinusoidal Obstruction Syndrome in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation.
Ansari M; Petrykey K; Rezgui MA; Del Vecchio V; Cortyl J; Ralph RO; Nava T; Beaulieu P; St-Onge P; Jurkovic Mlakar S; Huezo-Diaz Curtis P; Uppugunduri CRS; Lesne L; Théoret Y; Chalandon Y; Bartelink IH; Boelens JJ; Bredius RGM; Dalle JH; Lewis V; Kangarloo BS; Peters C; Sinnett D; Bittencourt H; Krajinovic M;
Biol Blood Marrow Transplant; 2020 May; 26(5):920-927. PubMed ID: 31790828
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetic analysis of intravenous busulfan: GSTA1 genotype is not a predictive factor of initial dose in Chinese adult patients undergoing hematopoietic stem cell transplantation.
Sun Y; Huang J; Hao C; Li Z; Liang W; Zhang W; Chen B; Yang W; Hu J
Cancer Chemother Pharmacol; 2020 Feb; 85(2):293-308. PubMed ID: 31834435
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of effects of busulfan and DMA on SOS in pediatric stem cell recipients.
Kerl K; Diestelhorst C; Bartelink I; Boelens J; Trame MN; Boos J; Hempel G
Pediatr Blood Cancer; 2014 Feb; 61(2):306-11. PubMed ID: 24174393
[TBL] [Abstract][Full Text] [Related]
13. Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation.
Srivastava A; Poonkuzhali B; Shaji RV; George B; Mathews V; Chandy M; Krishnamoorthy R
Blood; 2004 Sep; 104(5):1574-7. PubMed ID: 15142875
[TBL] [Abstract][Full Text] [Related]
14. Glutathione S-transferase A1 polymorphisms and acute graft-vs.-host disease in HLA-matched sibling allogeneic hematopoietic stem cell transplantation.
Kim I; Keam B; Lee KH; Kim JH; Oh SY; Ra EK; Yoon SS; Park SS; Kim CS; Park S; Hong YC; Kim BK
Clin Transplant; 2007; 21(2):207-13. PubMed ID: 17425746
[TBL] [Abstract][Full Text] [Related]
15. GSTA1 Genetic Variants and Conditioning Regimen: Missing Key Factors in Dosing Guidelines of Busulfan in Pediatric Hematopoietic Stem Cell Transplantation.
Nava T; Rezgui MA; Uppugunduri CRS; Curtis PH; Théoret Y; Duval M; Daudt LE; Ansari M; Krajinovic M; Bittencourt H
Biol Blood Marrow Transplant; 2017 Nov; 23(11):1918-1924. PubMed ID: 28807770
[TBL] [Abstract][Full Text] [Related]
16. Influence of GST gene polymorphisms on the clearance of intravenous busulfan in adult patients undergoing hematopoietic cell transplantation.
Kim SD; Lee JH; Hur EH; Lee JH; Kim DY; Lim SN; Choi Y; Lim HS; Bae KS; Noh GJ; Yun SC; Han SB; Lee KH
Biol Blood Marrow Transplant; 2011 Aug; 17(8):1222-30. PubMed ID: 21215809
[TBL] [Abstract][Full Text] [Related]
17. Influence of glutathione S-transferase gene polymorphisms on busulfan pharmacokinetics and outcome of hematopoietic stem-cell transplantation in thalassemia pediatric patients.
Ansari M; Huezo-Diaz P; Rezgui MA; Marktel S; Duval M; Bittencourt H; Cappelli B; Krajinovic M
Bone Marrow Transplant; 2016 Mar; 51(3):377-83. PubMed ID: 26691424
[TBL] [Abstract][Full Text] [Related]
18. Maximal concentration of intravenous busulfan as a determinant of veno-occlusive disease: a pharmacokinetic-pharmacodynamic analysis in 293 hematopoietic stem cell transplanted children.
Philippe M; Neely M; Rushing T; Bertrand Y; Bleyzac N; Goutelle S
Bone Marrow Transplant; 2019 Mar; 54(3):448-457. PubMed ID: 30108322
[TBL] [Abstract][Full Text] [Related]
19. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation.
Dignan FL; Wynn RF; Hadzic N; Karani J; Quaglia A; Pagliuca A; Veys P; Potter MN; ;
Br J Haematol; 2013 Nov; 163(4):444-57. PubMed ID: 24102514
[TBL] [Abstract][Full Text] [Related]
20. Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation.
Richardson PG; Smith AR; Triplett BM; Kernan NA; Grupp SA; Antin JH; Lehmann L; Miloslavsky M; Hume R; Hannah AL; Nejadnik B; Soiffer RJ
Br J Haematol; 2017 Jul; 178(1):112-118. PubMed ID: 28444784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
